NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) and HOPE Therapeutics, Inc. Announce Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

In This Article:

MIAMI, Sept. 3, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, ("NRx," the "Company") and HOPE Therapeutics, Inc., a medical and technology driven company and wholly-owned subsidiary of NRx, today announced they will be featured as a presenting companies at the H.C. Wainwright 26th Annual Global Investment Conference.  The conference is being held on September 9-11, 2024.

(PRNewsfoto/NRx Pharmaceuticals)

The in-person venue for the event is the Lotte New York Palace Hotel in New York City located at 455 Madison Avenue.  Virtual participation will be staged simultaneously with over 550 company presentations scheduled as live feed or available on-demand.

Jonathan Javitt, MD, MPH, Chairman and Chief Scientist of NRx and Co-CEO of Hope, will provide an overview of the Company's business during the presentation.

If you are an institutional investor, and would like to listen to the Company's presentation, please click on the following link (www.hcwevents.com/annualconference) to register for the conference. 

Event:  H.C. Wainwright 26th Annual Global Investment Conference

Date:  September 9-11, 2024

Location:  Virtual to start on-demand on September 9 at 7:00 A.M. (ET) or in-person at the Lotte New York Palace Hotel, New York, NY.

Access to the presentation can also be found at https://ir.nrxpharma.com/events beginning at 7:00AM ET Monday September 9, 2024.

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.